Repurposing cysteamine as a rapdily deployable intervention for COVID-19

Nylexa是一种重新设计的治疗方法，已经在CF患者胸部感染的高级开发中，可以迅速部署为COVID-19的治疗方法。Nylexa是独特的，可能会改变游戏规则，因为它有多个靶点; nSARS-CoV-2病毒，对感染的免疫反应以及继发于SARS-CoV-2的难治性细菌感染的并发症导致多达20%的目前COVID-19死亡人数的50%，在爆发早期（中国湖北省）超过50%。Nylexa是一种抗菌免疫调节剂，有可能改变这种疾病的发展轨迹。为了挽救生命，帮助那些永久性肺损伤较少的感染者更好地康复。Nylexa不仅是伟大的科学，也是一种真正可行的COVID-19解决方案：成本效益高，易于获得和可扩展，因此可以在成功后在全球范围内部署，加快临床测试和批准。作为一家领先的生物技术公司，NovaBiotics完全有能力提供这一成果，开发一流的抗感染和呼吸系统疾病疗法。通过与拥有生产和销售分销基础设施的制药实体合作，该业务在开发新药候选药物从发明到后期临床开发以及随后的商业化方面有着良好的记录。Nylexa不仅可以改变COVID-19大流行的结果，而且对于NovaBiotics来说也是如此。Nylexa可能成为NovaBiotics的第一个获批药物，并可能使业务转向盈利，使公司能够增长和再投资于研发，以推进公司的其他可能挽救生命的抗菌药物用于细菌和真菌疾病，这可能比Nylexa对社会和经济带来更大的好处。

Nylexa is a repurposed therapy, already in advanced development for chest infections in CF patients, that can be rapidly deployed as a treatment for COVID-19\.Nylexa is unique and potentially game-changing, because it has multiple targets; the nSARS-CoV-2 virus, the immune response to the infection and also the complications of intractable bacterial infections secondary to SARS-CoV-2 that result in as many as 20% of COVID-19 deaths currently and more than 50% early in the outbreak (in Hubei Province, China).Nylexa is an antimicrobial-immunomodulator with the potential to alter the trajectory of this disease. To save lives and aid better recovery of those infected with less permanent lung damage. It can be rapidly and safely tested (as an intravenously infused drug) in hospitalised COVID-19 patients in the UK and thereafter, worldwide.Nylexa isn't just great science, it is a truly viable solution to COVID-19: Cost effective, readily available and scalable, such that it can be deployed on the global scale required post successful, expedited clinical testing and approvals. NovaBiotics is perfectly positioned to deliver this outcome as a leading biotechnology company developing first-in-class anti-infective and respiratory disease therapies. The business has a track record of developing novel drug candidates from invention to late stage clinical development and commercialisation thereafter through partnerships with pharmaceutical entities with manufacturing and sales-distribution infrastructure.Nylexa could not only be transformational on outcomes of the COVID-19 pandemic, but for NovaBiotics. Nylexa could potentially become NovaBiotics' first approved drug and could pivot the business to profitability, allowing company growth and re-investment in research and development to advance the company's other, potentially life-saving antimicrobial medicines for bacterial and fungal disease, which could have even greater benefit to society and the economy than Nylexa.